Clinical Trial

A Long-term Follow-up Study in Participants Who Received CS-101

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-10; most recent amendment 2026-02-08.
Trial Details
NCT Number NCT06685536
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: First Affiliated Hospital of Guangxi Medical University
Conditions Beta-Thalassemia
Enrollment 5 participants
Start Date 2025-01-18
Primary Completion 2039-07 (estimated)
Study Completion 2039-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-10